Sugi Predict

Sugi Predict / Compounds / SCHEMBL401672

SCHEMBL401672

SCHEMBL401672

Cc1ccc(NC(=O)Nc2cc(CN3CCN4C(=O)OC[C@H]4C3)ccc2F)cn1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 2/20 0.42
▸ PARP1 P09874 4/20 0.40
▸ MTOR P42345 6/20 0.38
▸ PIK3R1 P27986 4/20 0.38
▸ MAPK8 P45983 3/20 0.38
▸ MAPK10 P53779 3/20 0.38
▸ KCNQ3 O43525 1/20 0.37
▸ KCNQ2 O43526 1/20 0.37
▸ GALR3 O60755 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ HTR2C P28335 1/20 0.37
▸ MAPK9 P45984 1/20 0.36
▸ CCR3 P51677 1/20 0.36
▸ ROCK2 O75116 1/20 0.36
▸ LIMK1 P53667 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL397586 1.00 LTA4H (0.42) LTA4HPARP1MTORPIK3R1MAPK8
SCHEMBL23573830 0.89 LTA4H (0.45) LTA4HPARP1ROCK2
SCHEMBL23573738 0.89 LTA4H (0.45) LTA4HPARP1ROCK2
SCHEMBL402765 0.88 LTA4H (0.41) LTA4HPARP1MTORPIK3R1MAPK8
SCHEMBL402476 0.88 LTA4H (0.41) LTA4HPARP1MTORPIK3R1MAPK8
SCHEMBL4238184 0.88 LTA4H (0.41) LTA4HPARP1MTORPIK3R1MAPK8
SCHEMBL3198756 0.85 SIRT2 (0.40) LTA4HPARP1MTORPIK3R1MAPK8
SCHEMBL3198667 0.85 SIRT2 (0.40) LTA4HPARP1MTORPIK3R1MAPK8
SCHEMBL400316 0.82 MAPK8 (0.38) MTORMAPK8MAPK10KCNQ3KCNQ2
SCHEMBL398396 0.82 MAPK8 (0.38) MTORMAPK8MAPK10KCNQ3KCNQ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US claimed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US claimed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US claimed
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2015-01-01 — — US claimed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US claimed
US-12264133-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2025-04-01 — — US disclosed
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US disclosed
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2009-10-01 — — US disclosed
US-20090099198-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-04-16 — — US disclosed
US-7507735-B2 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INC. (US) 2009-03-24 — — US disclosed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US disclosed
US-20070208000-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-09-06 — — US disclosed
US-20070197505-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-08-23 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 LTA4H 3839/4885PARP1 4871/4885MTOR 1762/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 LTA4H 4548/4885PARP1 4712/4885MTOR 773/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 LTA4H 4058/4885PARP1 4835/4885MTOR 1170/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 LTA4H 4058/4885PARP1 4835/4885MTOR 1170/4885
US-12264133-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 LTA4H 4058/4885PARP1 4835/4885MTOR 1170/4885
US-20090099198-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 LTA4H 4058/4885PARP1 4835/4885MTOR 1170/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 LTA4H 4058/4885PARP1 4835/4885MTOR 1170/4885
US-20070208000-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 LTA4H 3839/4885PARP1 4871/4885MTOR 1762/4885
US-20070197505-A1 Certain chemical entities, compositions and methods TNNC1, TNNI3, TNNT2 LTA4H 3020/4885PARP1 3956/4885MTOR 426/4885
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 LTA4H 4058/4885PARP1 4835/4885MTOR 1170/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 LTA4H 4058/4885PARP1 4835/4885MTOR 1170/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 LTA4H 4058/4885PARP1 4835/4885MTOR 1170/4885
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 LTA4H 4058/4885PARP1 4835/4885MTOR 1170/4885
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 LTA4H 4058/4885PARP1 4835/4885MTOR 1170/4885
US-20090247544-A1 Certain Chemical Entities, Compositions and Methods TNNC1, TNNI3, TNNT2 LTA4H 3020/4885PARP1 3956/4885MTOR 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.